D2 | Abstract 14

Annual NUTRIM Symposium 18 November 2020


Prevenar vaccination does not increase antibodies against oxLDL or phosphorylcholine in metabolic disease patients

Inês Magro dos Reis1, Tom Houben1, Yvonne Oligschlaeger1, Tim Hendrikx2, 3 Ger Koek4, Marit Westerterp5, Christoph Binder2,3, David Cassiman6, Ronit Shiri-Sverdlov1

Department of Molecular Genetics, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands
2 Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
3 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
4 Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands.
5 Department of Pediatrics, Section Molecular Genetics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
6 Department of Gastroenterology-Hepatology and Metabolic Center, University Hospitals Leuven, Leuven, Belgium

As a mediator between lipid metabolism dysfunction, oxidative stress and inflammation, oxLDL is a promising therapeutical target in a wide range of metabolic diseases. Previously, mouse studies showed that increasing anti-phosphorylcholine (PC) IgM antibody levels via pneumococcal immunization reduces atherosclerosis, non-alcoholic steatohepatitis and Niemann-Pick (NP) disease burden. Since PC is present in pneumococci and oxLDL alike, anti-PC antibodies cross-react with oxLDL, increasing its clearance. These findings suggest that pneumococcal vaccination may be a useful preventive and therapeutical metabolic strategy in patients with metabolic diseases.

In this pilot clinical trial, our aim was to determine whether vaccination with a pneumococcal conjugate vaccine increases anti-phosphorylcholine and/or anti-oxLDL IgM antibody levels in human patients with metabolic diseases.

Four partial lipodystrophy, three familiar hypercholesterolemia and two NPB patients received one active dose of a pneumococcal vaccine (Prevenar-13) and were followed-up for four weeks. Patients’ IgM and IgG antibody levels were measured in plasma samples taken just before and four weeks after Prevenar-13 vaccination.

No differences were observed in patients’ levels of anti-oxLDL IgM or IgG antibodies before and after Prevenar-13 vaccination. In addition, following Prevenar-13 vaccination, we observed a reduction in anti-PC IgM antibody levels, whereas no differences were observed in anti-PC IgG antibody titers.

Our findings indicate that Prevenar-13 vaccination does not induce an immune response against oxLDL in patients with metabolic diseases. Therefore, Prevenar-13 is not suited to target the metabolic disruptor and pro-inflammatory mediator oxLDL in patients.

NUTRIM | School of Nutrition and Translational Research in Metabolism
NUTRIM aims to contribute to health maintenance and personalised medicine by unraveling lifestyle and disease-induced derangements in metabolism and by developing targeted nutritional, exercise and drug interventions. This is facilitated by a state of the art research infrastructure and close interaction between scientists, clinicians, master and PhD students.